Eiropas Savienība - slovāku - EMA (European Medicines Agency)

ucb pharma s.a. - lakosamid - epilepsie, čiastočná - antiepileptiká, - lacosamide spoločnosti ucb je označené ako monotherapy a adjunctive terapie v liečbe čiastočné-nástup záchvaty s alebo bez sekundárnej zovšeobecnenie v dospelí, mladiství a deti od 4 rokov s epilepsiou.

Eiropas Savienība - slovāku - EMA (European Medicines Agency)

santen oy - netarsudil - glaucoma, open-angle; ocular hypertension - oftalmologiká - zníženie zvýšený vnútroočný tlak (iop) u dospelých pacientov s primárnym open-uhlom alebo očných hypertenzia.

Eiropas Savienība - slovāku - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - wet macular degeneration - oftalmologiká - beovu je indikovaný u dospelých na liečbu neovascular (mokré) vekom podmienená makulárna degenerácia (amd).

Eiropas Savienība - slovāku - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologiká - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Eiropas Savienība - slovāku - EMA (European Medicines Agency)

orion corporation - pregabalín - antiepileptiká - mačky - alleviation of acute anxiety and fear associated with transportation and veterinary visits.

Eiropas Savienība - slovāku - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetylfumarát - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Eiropas Savienība - slovāku - EMA (European Medicines Agency)

serb sa - betaine - homocystinúria - iné alimentárny trakt a metabolizmus výrobky, - amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in:•         cystathionine beta-synthase (cbs),•         5,10 methylene tetrahydrofolate reductase (mthfr),•         cobalamin cofactor metabolism (cbl).

Eiropas Savienība - slovāku - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Eiropas Savienība - slovāku - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologiká - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Eiropas Savienība - slovāku - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).